In a patient whose platelet count fell from 82 ×10⁹/L to 71 ×10⁹/L while on heparin products, what is the appropriate management for suspected heparin‑induced thrombocytopenia?

Immediate Management of Suspected HIT

Stop all heparin products immediately and start a non-heparin anticoagulant at therapeutic doses right now 1. This patient has a declining platelet count (82 to 71 ×10⁹/L) while on heparin, which is a red flag for heparin-induced thrombocytopenia (HIT), and delaying treatment significantly increases the risk of life-threatening thrombosis.

Why This is Urgent

The FDA label is explicit: if the platelet count falls below 100,000/mm³, promptly discontinue heparin, evaluate for HIT, and administer an alternative anticoagulant 1. Your patient is already at 71 ×10⁹/L (71,000/mm³), well below this threshold.

More critically, 50% of patients who receive only heparin cessation (without alternative anticoagulation) develop thrombotic events within 30 days 2. HIT causes a prothrombotic state through antibody-mediated platelet activation, leading to devastating complications including:

• Deep vein thrombosis and pulmonary embolism
• Stroke and myocardial infarction
• Limb ischemia requiring amputation
• Death 1

Step-by-Step Action Plan

1. Stop All Heparin Immediately

• Discontinue unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and heparin flushes
• Check all IV lines and catheters for heparin-containing solutions
• Do not wait for laboratory confirmation 2, 3

2. Start Alternative Anticoagulation Now

The 2018 ASH guidelines and 2012 ACCP guidelines recommend these options for patients with normal renal function 2, 3:

First-line choices:

• Argatroban (direct thrombin inhibitor)
• Danaparoid (if available in your region)
• Fondaparinux (increasingly used off-label, though less studied)

For specific situations:

• Bivalirudin if cardiac catheterization is needed 3

3. Do NOT Start Warfarin Yet

Critical pitfall to avoid: Warfarin should not be initiated until the platelet count recovers to at least 150 ×10⁹/L 3. Starting warfarin during acute HIT can cause venous limb gangrene and skin necrosis due to protein C depletion in a hypercoagulable state. When you do eventually start warfarin, overlap it with the alternative anticoagulant until the INR is therapeutic for 2 consecutive days 3.

4. Send Laboratory Tests

While treatment should not be delayed for results, order:

• Anti-PF4/heparin antibody assay (immunoassay like ELISA or CLIA)
• Functional assay if available (serotonin release assay has higher specificity) 2, 4

The immunoassays are highly sensitive but less specific—many positive results occur without clinical HIT. However, given this patient's clinical picture (falling platelets on heparin), the pretest probability is already high enough to treat.

5. Monitor Closely

• Daily platelet counts until recovery
• Watch for new thrombosis (even with thrombocytopenia, bleeding is rare—thrombosis is the danger)
• Monitor for bleeding complications from alternative anticoagulants 2

Dosing Considerations

Argatroban (if normal liver function):

• Initial infusion: 2 mcg/kg/min (reduce to 0.5-1.2 mcg/kg/min in hepatic impairment or critical illness)
• Target aPTT: 1.5-3 times baseline
• No renal dose adjustment needed 3

Danaparoid (if normal renal function):

• Bolus: 2,500 units IV, then infusion based on weight
• Requires dose adjustment in renal impairment 3

Common Pitfalls

1. Waiting for lab confirmation before stopping heparin - Don't do this. The thrombotic risk is too high.

2. Giving prophylactic doses of alternative anticoagulants - Use therapeutic doses even without thrombosis, as 50% will develop clots within 30 days if undertreated 2, 3.

3. Transfusing platelets prophylactically - Platelets should not be given for prophylaxis in HIT as they may worsen thrombosis 3.

4. Starting warfarin too early - Wait for platelet recovery to avoid limb gangrene 3.

Duration of Treatment

Continue alternative anticoagulation for at least 4 weeks if isolated HIT (no thrombosis), or 3-6 months if thrombosis develops 3. The antibodies typically clear within 50-100 days, after which the patient can potentially receive heparin again if absolutely necessary (though this requires antibody testing to confirm clearance) 3.